What is it about?
One of the major problem occurring to breast cancer patients is to know whether they are at low or high risk of reappearance of the tumour upon first treatment. The ability to distinguish between these two group of patients may have important implications to improve treatment outcomes. In this review, we discuss the potential use of the enzyme phospholipase Cγ1 as a potential predictive factor and a therapeutic target.
Featured Image
Read the Original
This page is a summary of: The role of phospholipase Cγ1 in breast cancer and its clinical significance, Future Oncology, September 2017, Future Medicine,
DOI: 10.2217/fon-2017-0125.
You can read the full text:
Contributors
The following have contributed to this page